Cibus (CBUS) Debt-to-Revenue : 5.51 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Cibus Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cibus's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $4.60 Mil. Cibus's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $32.14 Mil. Cibus's annualized Revenue for the quarter that ended in Sep. 2024 was $6.67 Mil. Cibus's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 was 5.51.

Cibus Debt-to-Revenue Historical Data

The historical data trend for Cibus's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cibus Debt-to-Revenue Chart

Cibus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

2.55

0.83

0.69

88.61

13.55

Cibus Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Revenue	Get a 7-Day Free Trial															13.90	5.58	10.49	11.24	5.51

Competitive Comparison of Cibus's Debt-to-Revenue

For the Biotechnology subindustry, Cibus's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cibus's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cibus's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cibus's Debt-to-Revenue falls into.

Cibus Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cibus's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(6.947	+	17.674)	/	1.817
	=	13.55

Cibus's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(4.597	+	32.142)	/	6.668
	=	5.51

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.

Cibus Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cibus's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cibus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cibus Inc (NAS:CBUS) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

6455 Nancy Ridge Drive, San Diego, CA, USA, 92121

Website

https://www.cibus.com

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

Executives

Gerhard Prante	director	SCHONE AUSSICHT 5, HOFHEIM A. TS 2M 65719
Gocal Gregory Francis William	officer: See Remarks	13737 BASSMORE DR., SAN DIEGO CA 92129
Rory B Riggs	director, officer: Chief Executive Officer	65 RAILROAD AVE, RIDGEFIELD NJ 07657
Collins James C. Jr.	director	1007 MARKET STREET, D-9058, WILMINGTON DE 19898
Jonathan Finn	10 percent owner	C/O VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Mark Terrence Finn	director	VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Jean-pierre Jules Lehmann	director	21 ALPINASTRASSE, CH 3780, GSTAAD V8 3780
Keith Allen Walker	director	13315 ROXTON CIRCLE, SAN DIEGO CA 92130
Wade Hampton King	officer: Chief Financial Officer	750 MEADOWOOD DRIVE, ASPEN CO 81611
Peter Beetham	director, officer: See Remarks	6455 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Yves J Ribeill	director	C/O CALYXT, INC., 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Michael A. Carr	director, officer: President and CEO	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
William Koschak	officer: Chief Financial Officer	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Sarah Reiter	officer: Chief Business Officer	202 COUSTEAU PLACE, DAVIS CA 95618
Daniel F Voytas	officer: Chief Science Officer	2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113